There are a large number of patients with hereditary ophthalmic diseases worldwide, with gene therapy drugs emerging as a powerful therapeutic tool in ophthalmology due to the limited efficacy of traditional treatments. As of 2021, ophthalmology ranks second in the gene therapy pipeline according to the number of treatments in development. There are many gene therapy drugs currently on the market, but basic research and clinical translation in ophthalmology face many difficulties, such as complicated operations, a long production period for experimental models, and expensive equipment. At Cyagen, we are dedicated to advancing this field with our comprehensive support for discovery and translational research, to help bring more effective and affordable treatments to patients with eye diseases.
With the continuous progress of gene-editing technology and the development of new delivery methods, the future of gene therapy for ocular diseases is very promising. Despite the complicated operations, a long production period for experimental models, and expensive equipment, companies and institutions are actively investing in research and development, and increasing numbers of clinical trials are being conducted to validate the safety and efficacy of these new treatments. The goal is to bring more effective and affordable treatments to patients with hereditary ophthalmic diseases and to improve their quality of life. As a leader in the gene therapy industry, we are dedicated to supporting and advancing this field and working towards the ultimate goal of providing hope and healing to those in need.
In recent years, gene therapy has emerged as a powerful tool in the field of ophthalmic disease research. By correcting genetic defects, it has become a lifesaving solution for some retinal diseases previously considered to be incurable. Gene editing is a critical component of gene therapy, involving targeted editing of the genome to recreate critical phenotypes in animals. However, delivery vectors are responsible for delivering the therapy to the eye to achieve therapeutic effects, and they continue to face issues of safety, specificity, and commercial viability.. This is a critical factor in current research and development. To overcome these technical challenges, it's best to hear from the experts on how they plan to break through these bottlenecks.
At Cyagen, our team of experts is dedicated to supporting preclinical ophthalmic gene therapy research. Register for this webinar now to learn more about our comprehensive services for preclinical ophthalmic gene therapy research.